DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026)
DBV Technologies (DBVT) reported Liabilities and Shareholders Equity of $266.4 million for Q1 2026, up 426.88% year-over-year from $50.6 million in Q1 2025, and up 13.99% quarter-over-quarter from $233.7 million in Q4 2025.
DBV Technologies (DBVT) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $266.4 million in Q1 2026.
- Liabilities and Shareholders Equity for Q1 2026 came in at $266.4 million, up 426.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $754.0 million (up 133.11% YoY), and the FY2025 annual result was $233.7 million, up 255.94% from the prior year.
- Liabilities and Shareholders Equity advanced to $266.4 million in Q1 2026 per DBVT's latest filing, from $233.7 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $285.0 million in Q2 2022 and troughed at $50.6 million in Q1 2025.
- A 5-year average of $173.2 million and a median of $183.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity tumbled 65.34% in 2025, then jumped 426.88% in 2026.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $246.5 million in 2022, then retreated by 25.77% to $183.0 million in 2023, then slumped by 64.12% to $65.7 million in 2024, then surged by 255.94% to $233.7 million in 2025, then advanced by 13.99% to $266.4 million in 2026.
- Business Quant data shows DBVT's Liabilities and Shareholders Equity at $266.4 million in Q1 2026, $233.7 million in Q4 2025, and $110.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 37.37 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 811.27 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 14.93 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.73 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 23.64 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 33.89 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 12.81 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 26.48 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 640.56 Mn |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | 266.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 266.40 Mn |
| Dec 31, 2025 | 233.70 Mn |
| Sep 30, 2025 | 110.50 Mn |
| Jun 30, 2025 | 143.43 Mn |
| Mar 31, 2025 | 50.56 Mn |
| Dec 31, 2024 | 65.66 Mn |
| Sep 30, 2024 | 93.06 Mn |
| Jun 30, 2024 | 114.19 Mn |
| Mar 31, 2024 | 145.90 Mn |
| Dec 31, 2023 | 182.99 Mn |
| Sep 30, 2023 | 189.78 Mn |
| Jun 30, 2023 | 217.52 Mn |
| Mar 31, 2023 | 232.93 Mn |
| Dec 31, 2022 | 246.52 Mn |
| Sep 30, 2022 | 248.12 Mn |
| Jun 30, 2022 | 284.98 Mn |
| Mar 31, 2022 | 117.58 Mn |
| Dec 31, 2021 | 146.72 Mn |
| Sep 30, 2021 | 170.92 Mn |
| Jun 30, 2021 | 200.58 Mn |